Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of$8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of$25 million and annual revenue of $85.9 million New credit facilities’ favorable interest rates and amortization schedules free up approximately$19 million in cash in 2025 In-licensed two new Ionis assets in Canada to drive long-term growth MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or t ...